System of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients

Abstract

The invention discloses a system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients. The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients includes an input device, a computing device and an output device, wherein the computing device includes a memory and a processor; a computer program is saved in the memory;the processor is configured to execute the computer program saved in the memory so as to realize the algorithm of a discrimination function; and the discrimination function returns the short-term prognosis of hepatorenal syndrome patients to be tested through liver cancer history, creatinine (Cr), neutrophilic granulocyte percentage (NE%) and glutamic-pyruvic transaminase (ALT). The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients performs analysis and comparison by means of the current easily obtained clinic lab test index, establishes a survival prognosis scoring model for hepatic cirrhosis and hepatorenal syndrome patients, and guides the patients to further complete the related treatment to prolong the survival time of the patients.

Description

Technical field [0001] The present disclosure relates to the field of medicine, in particular, to a system for determining the short-term prognosis of patients with liver cirrhosis and hepatorenal syndrome. Background technique [0002] Liver cirrhosis hepatorenal syndrome (hepatorenal syndrome, HRS) is a functional renal failure that appears on the basis of severe liver disease. Its typical clinical manifestations are spontaneous oliguria or anuria, azotemia, dilutional hyponatremia and hyponatremia. Liver cirrhosis and hepatorenal syndrome are clinically divided into type I and type II. Type I HRS blood creatinine increases more than 2 times within 2 weeks, reaching or exceeding 226 μmol / L, and type II HRS blood creatinine increases between 133 and 226 μmol / L between. Type Ⅰ HRS is serious, with a rapid progress, with a median survival time of 2 weeks; Type Ⅱ HRS progresses relatively slowly, with relatively mild liver and kidney damage, with a median survival time of 6 month...

AI Technical Summary

Problems solved by technology

However, there is still a lack of a more effective method for judging the short-term prognosis of patients with liver cirrhosis and hepatorenal syndrome in my country

Images